Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rawlins: Seek More Joint Scientific Advice for your PIMs

This article was originally published in Scrip

Executive Summary

Not enough companies that have won coveted PIM designations for their novel drugs are making use of joint scientific advice meetings with UK regulators, the MHRA and NICE, and are instead focusing on guidance from the European Medicine Agency – a situation that needs to change, says MHRA Chairman Sir Michael Rawlins. He added that the two bodies are also working together to bridge the gap that has opened up for products between the scheme and their NICE evaluation.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC029530

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel